175 related articles for article (PubMed ID: 38085235)
1. Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage.
Catalano F; Vlaar EC; Dammou Z; Katsavelis D; Huizer TF; Zundo G; Hoogeveen-Westerveld M; Oussoren E; van den Hout HJMP; Schaaf G; Pike-Overzet K; Staal FJT; van der Ploeg AT; Pijnappel WWMP
Hum Gene Ther; 2024 Apr; 35(7-8):256-268. PubMed ID: 38085235
[TBL] [Abstract][Full Text] [Related]
2. Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II.
Catalano F; Vlaar EC; Katsavelis D; Dammou Z; Huizer TF; van den Bosch JC; Hoogeveen-Westerveld M; van den Hout HJMP; Oussoren E; Ruijter GJG; Schaaf G; Pike-Overzet K; Staal FJT; van der Ploeg AT; Pijnappel WWMP
Mol Ther Methods Clin Dev; 2023 Dec; 31():101149. PubMed ID: 38033460
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of
Smith MC; Belur LR; Karlen AD; Erlanson O; Podetz-Pedersen KM; McKenzie J; Detellis J; Gagnidze K; Parsons G; Robinson N; Labarre S; Shah S; Furcich J; Lund TC; Tsai HC; McIvor RS; Bonner M
Hum Gene Ther; 2022 Dec; 33(23-24):1279-1292. PubMed ID: 36226412
[TBL] [Abstract][Full Text] [Related]
4. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
[TBL] [Abstract][Full Text] [Related]
5. A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation.
Mashima R; Ohira M; Okuyama T; Onodera M; Takada S
Sci Rep; 2023 May; 13(1):7865. PubMed ID: 37188686
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic Stem Cell Gene Therapy Corrects Neuropathic Phenotype in Murine Model of Mucopolysaccharidosis Type II.
Wakabayashi T; Shimada Y; Akiyama K; Higuchi T; Fukuda T; Kobayashi H; Eto Y; Ida H; Ohashi T
Hum Gene Ther; 2015 Jun; 26(6):357-66. PubMed ID: 25761450
[TBL] [Abstract][Full Text] [Related]
7. An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II.
Das S; Rruga F; Montepeloso A; Dimartino A; Spadini S; Corre G; Patel J; Cavalca E; Ferro F; Gatti A; Milazzo R; Galy A; Politi LS; Rizzardi GP; Vallanti G; Poletti V; Biffi A
Mol Ther; 2024 Mar; 32(3):619-636. PubMed ID: 38310355
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR
BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547
[TBL] [Abstract][Full Text] [Related]
9. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.
Wood SR; Chaudrhy A; Ellison S; Searle R; Burgod C; Tehseen G; Forte G; O'Leary C; Gleitz H; Liao A; Cook J; Holley R; Bigger BW
Hum Gene Ther; 2024 Apr; 35(7-8):232-242. PubMed ID: 37212263
[TBL] [Abstract][Full Text] [Related]
10. Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy.
Miwa S; Watabe AM; Shimada Y; Higuchi T; Kobayashi H; Fukuda T; Kato F; Ida H; Ohashi T
Mol Genet Metab; 2020 Aug; 130(4):262-273. PubMed ID: 32631737
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.
Jung SC; Park ES; Choi EN; Kim CH; Kim SJ; Jin DK
Mol Cells; 2010 Jul; 30(1):13-8. PubMed ID: 20652491
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
[TBL] [Abstract][Full Text] [Related]
13. Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome.
Arguello A; Meisner R; Thomsen ER; Nguyen HN; Ravi R; Simms J; Lo I; Speckart J; Holtzman J; Gill TM; Chan D; Cheng Y; Chiu CL; Dugas JC; Fang M; Lopez IA; Solanoy H; Tsogtbaatar B; Zhu Y; Bhalla A; Henne KR; Henry AG; Delucchi A; Costanzo S; Harris JM; Diaz D; Scearce-Levie K; Sanchez PE
JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622797
[TBL] [Abstract][Full Text] [Related]
14. Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II.
Hoshina H; Shimada Y; Higuchi T; Kobayashi H; Ida H; Ohashi T
Mol Genet Metab; 2018 Feb; 123(2):118-122. PubMed ID: 29289480
[TBL] [Abstract][Full Text] [Related]
15. A method for measuring disease-specific iduronic acid from the non-reducing end of glycosaminoglycan in mucopolysaccharidosis type II mice.
Shimada Y; Wakabayashi T; Akiyama K; Hoshina H; Higuchi T; Kobayashi H; Eto Y; Ida H; Ohashi T
Mol Genet Metab; 2016 Feb; 117(2):140-3. PubMed ID: 26051019
[TBL] [Abstract][Full Text] [Related]
16. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
Brusius-Facchin AC; Abrahão L; Schwartz IV; Lourenço CM; Santos ES; Zanetti A; Tomanin R; Scarpa M; Giugliani R; Leistner-Segal S
Gene; 2013 Sep; 526(2):150-4. PubMed ID: 23707223
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
[TBL] [Abstract][Full Text] [Related]
18. Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase.
Kosuga M; Mashima R; Hirakiyama A; Fuji N; Kumagai T; Seo JH; Nikaido M; Saito S; Ohno K; Sakuraba H; Okuyama T
Mol Genet Metab; 2016 Jul; 118(3):190-197. PubMed ID: 27246110
[TBL] [Abstract][Full Text] [Related]
19. Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing.
Laoharawee K; DeKelver RC; Podetz-Pedersen KM; Rohde M; Sproul S; Nguyen HO; Nguyen T; St Martin SJ; Ou L; Tom S; Radeke R; Meyer KE; Holmes MC; Whitley CB; Wechsler T; McIvor RS
Mol Ther; 2018 Apr; 26(4):1127-1136. PubMed ID: 29580682
[TBL] [Abstract][Full Text] [Related]
20. Expression of the two iduronate-2-sulfatase cDNAs.
Daniele A; Di Natale P
Biochem Mol Biol Int; 1995 Jun; 36(2):311-7. PubMed ID: 7663435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
